You just read:

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019

News provided by

Eiger BioPharmaceuticals, Inc.

Apr 11, 2019, 16:05 ET